A phase III, randomized, double-blind, placebo-controlled, parallel-group, three-arm, multinational, multicenter study to evaluate the efficacy and safety of subcutaneous amlitelimab injection in participants 3 years of age and older with moderate to severe atopic dermatitis receiving background topical corticosteroid therapy.